News Zydus follows Lupin with Myrbetriq settlement deal Zydus has joined Lupin in agreeing to settle patent litigation with Astellas on its generic of big-selling overactive bladder drug Myrbetriq.
News Lupin settles Myrbetriq patent spat with Astellas for $90m Lupin will be able to keep its generic of Astellas' overactive bladder therapy Myrbetriq on the US market, after reaching a settlement agreement.
News 'Skinny' generic Vascepa label case reaches US Supreme Court SCOTUS has agreed to hear a patent dispute between Amarin and Hikma that could have implications for 'skinny labels' used by generic manufacturers.
News Court blocks HHS' 340B rebate programme pilot Hospitals that challenged a US pilot of a new rebate model for medicines provided to low-income people have won another legal victory.
News Bayer's Monsanto sues mRNA COVID-19 vaccine makers Lawsuits filed by Bayer in the US are seeking damages and royalties on sales of COVID-19 shots sold by Pfizer/BioNTech, Moderna, and J&J.
News Judge blocks HHS' 340B rebate pilot at 11th hour A federal judge in the US has granted a restraining order that will stop the 340B rebate model from launching as planned on 1st January.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.